Levels of Osteoprotegerin (OPG) and Receptor Activator for Nuclear Factor Kappa B Ligand (RANKL) in Serum: Are They of Any Help?

Overview

Journal Wien Med Wochenschr

Specialty General Medicine

Date 2010 Aug 18

PMID 20714810

Citations 25

Authors

Doris Wagner

Astrid Fahrleitner-Pammer

Affiliations

Soon will be listed here.

Abstract

The coupling of bone formation and resorption is mediated through the OPG/RANK/RANKL system. OPG and RANKL are mainly produced by osteoblasts but also a variety of other tissues. The binding of RANKL to RANK, its natural receptor which is expressed by osteoclasts, accelerates bone resorption. OPG acts as decoy receptor and prevents the interaction of RANKL with RANK and therefore leads to a decrease in activity, survival and proliferation of osteoclasts. Since assays for measurements of serum OPG and RANKL have become commercially available, intense research focused on serum OPG/RANKL levels in context with underlying disease, age, co-morbidities, bone density, and fractures has derived. This review aims to provide an overview if and to which extent serum OPG and RANKL levels may reflect bone metabolism in patients with osteoporosis and metabolic bone disease.

Citing Articles

Genetic Variants in RANK and OPG Could Influence Disease Severity and Bone Remodeling in Patients with Early Arthritis.

Triguero-Martinez A, Pardines M, Montes N, Ortiz A, de la Iglesia-Cedeira A, Valero-Martinez C Life (Basel). 2024; 14(9).

PMID: 39337893 PMC: 11433004. DOI: 10.3390/life14091109.

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19.

Kazemi-Sufi S, Alipour S, Rabieepour M, Roshan-Milani S, Naderi R BMC Infect Dis. 2024; 24(1):1047.

PMID: 39333916 PMC: 11428542. DOI: 10.1186/s12879-024-09941-6.

Associations of dietary inflammatory index scores and serum inflammatory factors with the risk of osteoporosis: a cross-sectional study from Xinjiang, China.

Tong M, Zhang H, Li Y, Fu W, Luo T, Dai J J Orthop Surg Res. 2024; 19(1):423.

PMID: 39039571 PMC: 11264401. DOI: 10.1186/s13018-024-04866-x.

The relationship between dietary inflammatory index and osteoporosis among chronic kidney disease population.

Meng X, Sha W, Lou X, Chen J Sci Rep. 2023; 13(1):22867.

PMID: 38129528 PMC: 10739725. DOI: 10.1038/s41598-023-49824-5.

The reverse association of dietary antioxidant index with osteoporosis in postmenopausal iranian women: A case-control study.

Solgi S, Zayeri F, Abbasi B J Res Med Sci. 2023; 28:64.

PMID: 38024517 PMC: 10668208. DOI: 10.4103/jrms.jrms_143_22.

References

Santori C, Ceccanti M, Diacinti D, Attilia M, Toppo L, DErasmo E . Skeletal turnover, bone mineral density, and fractures in male chronic abusers of alcohol. J Endocrinol Invest. 2008; 31(4):321-6. DOI: 10.1007/BF03346365. View

Dai Y, Shen L . Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women. Chin Med J (Engl). 2007; 120(22):2017-21. View

Trofimov S, Pantsulaia I, Pantsulaia I, Kobyliansky E, Livshits G . Circulating levels of receptor activator of nuclear factor-kappaB ligand/osteoprotegerin/macrophage-colony stimulating factor in a presumably healthy human population. Eur J Endocrinol. 2004; 150(3):305-11. DOI: 10.1530/eje.0.1500305. View

Hofbauer L, Schoppet M . Serum measurement of osteoprotegerin--clinical relevance and potential applications. Eur J Endocrinol. 2001; 145(6):681-3. DOI: 10.1530/eje.0.1450681. View

Oh K, Rhee E, Lee W, Kim S, Baek K, Kang M . Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males. Clin Endocrinol (Oxf). 2005; 62(1):92-8. DOI: 10.1111/j.1365-2265.2004.02179.x. View

Yasuda H, Shima N, Nakagawa N, Mochizuki S, Yano K, Fujise N . Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology. 1998; 139(3):1329-37. DOI: 10.1210/endo.139.3.5837. View

Zhao H, Liu J, Ning G, Zhao Y, Chen Y, Sun L . Relationships between insulin-like growth factor-I (IGF-I) and OPG, RANKL, bone mineral density in healthy Chinese women. Osteoporos Int. 2007; 19(2):221-6. DOI: 10.1007/s00198-007-0440-y. View

Schett G, Kiechl S, Redlich K, Oberhollenzer F, Weger S, Egger G . Soluble RANKL and risk of nontraumatic fracture. JAMA. 2004; 291(9):1108-13. DOI: 10.1001/jama.291.9.1108. View

Messalli E, Mainini G, Scaffa C, Cafiero A, Salzillo P, Ragucci A . Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women. Maturitas. 2006; 56(1):38-44. DOI: 10.1016/j.maturitas.2006.05.007. View

10.

Bucay N, Sarosi I, Dunstan C, Morony S, Tarpley J, Capparelli C . osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12(9):1260-8. PMC: 316769. DOI: 10.1101/gad.12.9.1260. View

11.

Coen G, Ballanti P, Balducci A, Calabria S, Fischer M, Jankovic L . Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant. 2002; 17(2):233-8. DOI: 10.1093/ndt/17.2.233. View

12.

Simonet W, Lacey D, Dunstan C, Kelley M, Chang M, Luthy R . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997; 89(2):309-19. DOI: 10.1016/s0092-8674(00)80209-3. View

13.

Rogers A, Eastell R . Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab. 2005; 90(11):6323-31. DOI: 10.1210/jc.2005-0794. View

14.

Ohwada R, Hotta M, Sato K, Shibasaki T, Takano K . The relationship between serum levels of estradiol and osteoprotegerin in patients with anorexia nervosa. Endocr J. 2007; 54(6):953-9. DOI: 10.1507/endocrj.k07-034. View

15.

Vis M, Havaardsholm E, Haugeberg G, Uhlig T, Voskuyl A, van de Stadt R . Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2006; 65(11):1495-9. PMC: 1798341. DOI: 10.1136/ard.2005.044198. View

16.

Mizuno A, Amizuka N, Irie K, Murakami A, Fujise N, Kanno T . Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 1998; 247(3):610-5. DOI: 10.1006/bbrc.1998.8697. View

17.

Anderson D, Maraskovsky E, Billingsley W, Dougall W, Tometsko M, Roux E . A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997; 390(6656):175-9. DOI: 10.1038/36593. View

18.

Bernstein C . Inflammatory bowel diseases as secondary causes of osteoporosis. Curr Osteoporos Rep. 2006; 4(3):116-23. DOI: 10.1007/s11914-996-0031-4. View

19.

Reyes-Garcia R, Munoz-Torres M, Fernandez Garcia D, Mezquita-Raya P, Garcia Salcedo J, Luna J . Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis. Menopause. 2009; 17(1):140-4. DOI: 10.1097/gme.0b013e3181ac0cc1. View

20.

Nabipour I, Larijani B, Vahdat K, Assadi M, Jafari S, Ahmadi E . Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory. Menopause. 2009; 16(5):950-5. DOI: 10.1097/gme.0b013e3181a181b8. View